Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Desmond Curran

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|September 27, 2018
The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III TrialKenneth E Schmader, Myron J Levin, Katrijn Grupping, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|June 30, 2018
Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and OlderDesmond Curran, Lidia Oostvogels, Thomas Heineman, et al.
Expert Review of Vaccines|July 21, 2018
Development of adjuvanted recombinant zoster vaccine and its implications for shingles preventionNicolas Lecrenier, Pierre Beukelaers, Romulo Colindres, et al.
Influenza and Other Respiratory Viruses|February 5, 2024
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of ageDesmond Curran, Sean Matthews, Eliazar Sabater Cabrera, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 9, 2019
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT)Desmond Curran, Sean Matthews, Scott D Rowley, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|September 27, 2018
The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III TrialKenneth E Schmader, Myron J Levin, Katrijn Grupping, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|June 30, 2018
Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and OlderDesmond Curran, Lidia Oostvogels, Thomas Heineman, et al.
Expert Review of Vaccines|July 21, 2018
Development of adjuvanted recombinant zoster vaccine and its implications for shingles preventionNicolas Lecrenier, Pierre Beukelaers, Romulo Colindres, et al.
Influenza and Other Respiratory Viruses|February 5, 2024
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of ageDesmond Curran, Sean Matthews, Eliazar Sabater Cabrera, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 9, 2019
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT)Desmond Curran, Sean Matthews, Scott D Rowley, et al.
Pageof 9